Cardiometabolic Disorders News

PHILADELPHIA — Chronic kidney disease assessment and monitoring by albuminuria and estimated glomerular filtration rate is necessary for delivering goal-directed therapies to people with diabetes, according to a speaker.

PHILADELPHIA — An interactive, data-driven tool can individualize care for people with type 2 diabetes while promoting shared decision-making between clinicians and patients, according to a speaker at the Heart in Diabetes CME conference.

PHILADELPHIA — In this Healio video exclusive, Joshua J. Joseph, MD, MPH, FAHA, discussed the recent American Heart Association scientific statement on health equity in managing CV risk in type 2 diabetes.

PHILADELPHIA — Insulin resistance and beta-cell failure begin long before a diagnosis of prediabetes and aggressive treatment should begin as early as possible to reduce risk for a variety of complications, according to a speaker.

PHILADELPHIA — Coronary artery calcium scoring is a helpful tool in patients aged 40 years or older whom a decision to start therapy for primary CVD prevention is not obvious, a speaker said at the Heart in Diabetes CME conference.

In a cohort of healthy young adult men, one night of sleep deprivation attenuated the adaptation to recurrent hypoglycemia by preserving neuroendocrine counterregulation and subjective awareness, according to study findings.

PHILADELPHIA — The CV complications of COVID-19 are wide-ranging, and the consequences can be especially serious in patients with HF, a speaker said at the Heart in Diabetes CME conference.

PHILADELPHIA — The question of who should take aspirin is a complicated one and public messaging on it is sometimes confusing, a speaker said at the Heart in Diabetes CME conference.

PHILADELPHIA — Multiple, evidence-based strategies can decrease CV events in high-risk people with diabetes, yet clinicians must individualize approaches based on patient preference, individual risk factors and cost, according to a speaker.

For decades, clinicians and researchers have recognized that some people with type 2 diabetes of short duration who adhere to intensive glucose-lowering therapy can achieve normal blood glucose levels and discontinue treatment.